POMEZIA, Italy, Oct. 20, 2022 /PRNewswire/ — Alfasigma S.p.A. has accomplished the acquisition of SOFAR S.p.A., thus formally starting the integrating means of the 2 corporations.
The transaction, which was launched final August and was scheduled for completion in October 2022, was efficiently accomplished in full compliance with the deliberate timeline.
Alfasigma is likely one of the main multinational pharmaceutical corporations with over €1 billion turnover in 2021, R&D amenities in Bologna and Pomezia, 3 manufacturing crops in Italy and a pair of overseas, about 3,000 workers, an on-site presence in 17 markets plus an oblique presence in about 70 international locations.
SOFAR is an Italian pharmaceutical firm energetic within the analysis, manufacturing, and advertising and marketing of medication, medical gadgets, and dietary dietary supplements -with a long-standing custom and well-known to professionals and patients- with a turnover of greater than 100 million, 150 references marketed in additional than 10 therapeutic areas and 300 workers worldwide.
Moreover, SOFAR brings in 54 years of historical past within the area of gastroenterology and a product portfolio extremely complementary to the Alfasigma’s one.
“This acquisition,” says Stefano Golinelli, Chairman of Alfasigma, “will get our company the ultimate consolidation in the Italian market and an even stronger focus in the gastroenterology area, thus adding into our company’s ambitious growth strategy and taking up the challenge strongly wished by my father, Cavaliere Marino Golinelli, to always look ahead to the future“.
Both corporations are sensibly inclined to innovation. SOFAR specifically has developed, by the Kilometro Rosso Science and Technology Park in Bergamo, a middle of excellence in microbiota analysis, whereas Alfasigma is creating a pipeline of merchandise targeted on the gastrointestinal space.
The integration between the 2 corporations, by the enhancement of their respective scientific know-how, will allow an much more main positioning within the gastrointestinal space, an space through which SOFAR information greater than 80 % of its gross sales.
“Alfasigma has a clear goal in mind: to focus on innovation, to become increasingly stronger on the gastrointestinal area and to maximize the international market’s potential. We are one of the leading multinational pharmaceutical companies with Italian capital, we’re starting from a solid present which is at the same time full of potential for the future, with great opportunities for improvement,” explains Francesco Balestrieri Chief Executive Officer of Alfasigma who provides, “We want to be more international, more specialty care and more focused on the gastroenterological area. We still have ample room to develop the current portfolio, starting by the international expansion of the Consumer Healthcare division. The physiological growth will take place together with a major inorganic development both globally and in Europe in order to develop our R&D pipeline in Gastro specialty areas. The goal is to more than double our revenues in 10 years” notes the CEO.
The synergy between the 2 corporations will result in the enlargement of Alfasigma’s product vary in Italy and in overseas markets, including to its portfolio SOFAR’s merchandise: Pentacol, Enterolactis and Gerdoff for the gastrointestinal space; Cistiflux and Siler for the gynecological/urological space.
For extra data:
www.alfasigma.com
Logo – https://mma.prnewswire.com/media/1325576/Alfasigma_Logo.jpg
View unique content material:https://www.prnewswire.co.uk/news-releases/alfasigma-acquires-the-entire-share-capital-of-sofar-an-italian-pharmaceutical-company-301653860.html
